Patents Assigned to TCP Innovations Limited
  • COMBINATION OF DROLOXIFENE AND CLOPIDOGREL
    Publication number: 20130005762
    Abstract: The invention relates to the composition and use of a medicament comprising a fixed dose combination of droloxifene and clopidogrel.
    Type: Application
    Filed: December 1, 2010
    Publication date: January 3, 2013
    Applicant: TCP Innovations Limited
    Inventor: David John Grainger
  • ApoE mimetic agents
    Patent number: 8063106
    Abstract: The invention provides low molecular weight apoE mimetic agents suitable for preparing a medicament to treat autoimmune, inflammatory or neurodegenerative disease, (X)a-L-(X)b(Formula (I)) wherein each X is a (potentially different) chemical moiety bearing a positive charge at physiological pH a and b are, independently, numbers between 3 and 6; and L is a linker.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: November 22, 2011
    Assignee: TCP Innovations Limited
    Inventors: David J. Grainger, David John Fox
  • Methods for the diagnosis and treatment of bone disorders
    Patent number: 7901873
    Abstract: This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: March 8, 2011
    Assignee: TCP Innovations Limited
    Inventors: Jeremy Kirk Nicholson, Elaine Holmes, John Christopher Lindon, Joanne Tracey Brindle, David John Grainger
  • TGF-BETA STIMULANT AND FURTHER AGENT TO REDUCE SIDE EFFECTS
    Publication number: 20100099642
    Abstract: The invention relates to the use of TGF-beta stimulating agents, and in particular members of the triphenylethylene class of pharmaceutical agents, for the prevention, prophylaxis, treatment or amelioration of symptoms of cardiovascular disease, autoimmune diseases or neurodegeneration. In particular, improved compositions consisting of triphenylethylene agents combined with one or more additional active pharmaceutical agents in order to mitigate against side-effects of the triphenylethylene are described and claimed.
    Type: Application
    Filed: February 7, 2008
    Publication date: April 22, 2010
    Applicant: TCP Innovations Limited
    Inventor: David J. Grainger